Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02885181 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02885181 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 83 participants.
The verdict
NCT02885181, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of GS-9876 versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) in participants with active RA as measured by change from baseline in Disease Activity Score for 28 joint count using C-reactive protein (CRP) (DAS28 (CRP)) at Week 12.
Interventions
- DRUG Methotrexate
- DRUG Filgotinib
- DRUG Filgotinib placebo
- DRUG GS-9876
- DRUG GS-9876 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2016-09-21 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02885181
The ClinicalTrials.gov registry entry for NCT02885181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methotrexate is the first listed.
NCT02885181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02885181 about?
NCT02885181 is a clinical study titled "Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate". The primary objective of this study is to evaluate the effect of GS-9876 versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) in participants with active RA as measured by change from baseline in Disease Activity Score for 28 joint count using C-reactive protein (CRP) ...
What is the current status of trial NCT02885181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2016-09-21. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT02885181?
The interventions under investigation include: Methotrexate (DRUG), Filgotinib (DRUG), Filgotinib placebo (DRUG), GS-9876 (DRUG), GS-9876 placebo (DRUG).
Who is sponsoring clinical trial NCT02885181?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.